Concepedia

David Grayzel

DG

15

Publications

1.5K

Citations

14

H-Index

2006

Active since

Affiliations

Infinity Pharmaceuticals (United States)(Current)

Dana-Farber Cancer Institute

Harvard University

Eli Lilly (United States)

Massachusetts General Hospital

David Grayzel is an author at Infinity Pharmaceuticals (United States) specializing in medicine, cancer therapeutics, and radiation oncology.

Top concepts

Publications per year

2006–2017

15

Publications

15

Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study

David W. Dodick, Peter J. Goadsby, Egilius L.H. Spierings et al. · The Lancet Neurology · 2014 · 363 citations

, , +6

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

Lecia V. Sequist, Scott Gettinger, Neil Senzer et al. · Journal of Clinical Oncology · 2010 · 330 citations · Full text

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90

Jens Sydor, Emmanuel Normant, Christine Pien et al. · Proceedings of the National Academy of Sciences · 2006 · 226 citations · Full text

, , +13

Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I–induced leukemia and suppresses leukemic stem cells

Cong Peng, Julia Brain, Yiguo Hu et al. · Blood · 2007 · 145 citations · Full text

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen et al. · Clinical Cancer Research · 2013 · 83 citations · Full text

Rows per page

1–5 of 15